Skip to navigation

Axl

Axl is an receptor tyrosine kinase that is implicated in advanced clinical stage lung cancer and correlated with poor clinical outcomes. Axl can be dysregulated in certain cancers through increased protein expression or gene rearrangement, resulting in abnormal tumor growth and tumor cell survival. Axl has also been linked to resistance to EGFR inhibitors such as Tarceva® and Erbitux®.

Trials Targeting Axl

Indications: Non-Small Cell Lung Cancer
 
Drug Candidate: MGCD265
 
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of MGCD265 as a treatment for non-small cell lung cancer whose tumors carry genetic alterations of MET and Axl. Mirati and/or participating trial sites will analyze the molecular profile of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.



Indications: Head and Neck Squamous Cell Carcinoma
 
Drug Candidate: MGCD265
 
Driver Mutations: MET, Axl

A Phase 1 study evaluating the effects of MGCD265 as a treatment for head and neck cancer whose tumors carry genetic alterations of MET and Axl. Participating trial sites will analyze the genetic sequence of the tumors of eligible patients to determine if those mutations are present before enrolling in the clinical trial.


Tarceva® is a registered trademark of OSI Pharmaceuticals, LLC.
Erbitux® is a registered trademark of ImClone LLC.

Find an Active Trial